Novo Nordisk has been firmly thrust into the limelight given the kerfuffle that has accompanied the stellar showing of semaglutide for obesity, but much of the Danish drugmaker’s focus is to seek out innovation in the diabetes space that has been its bread and butter.
That is the position of Tomas Landh who for the last decade has headed up Novo’s innovation sourcing team. Speaking at the BIO-Europe meeting in Stockholm, Sweden this week, he pointed out that the Copenhagen-based group had been seen primarily as a diabetes company for decades and the importance of this field to the firm has not shifted
